AngioDynamics delivered strong Q3 results, highlighting growth across its MedTech portfolio. With raised guidance and increasing adoption in key areas like Mechanical Thrombectomy and NanoKnife ...

Pulmonary embolism (PE) is a significant cause of morbidity and mortality, particularly in patients classified as acute, ...

LATHAM, N.Y. (AP) — LATHAM, N.Y. (AP) — AngioDynamics Inc. (ANGO) on Wednesday reported a loss of $4.4 million in its fiscal third quarter. On a per-share basis, the Latham, New York-based ...

AngioDynamics, Inc. ANGO reported an adjusted earnings per share (EPS) of 3 cents for third-quarter fiscal 2025, narrower than the year-ago quarter’s adjusted loss per share of 16 cents and ...

H.C. Wainwright raised the firm’s price target on AngioDynamics (ANGO) to $16 from $15 and keeps a Buy rating on the shares. The company ...

08:34 EDT AngioDynamics (ANGO) up 13% in pre-market at $10.90 after Q3 results, guidance raise Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment ...

AngioDynamics expects full-year results to range from a loss of 34 cents per share to a loss of 31 cents per share, with revenue in the range of $285 million to $288 million.